In this epsisode Prof. Francisco Giorgino & Dr. Vanita Aroda explore how vital it is that we aim to control more than blood glucose levels when treating type 2 diabetes patients and whether we should strive for a balance by achieving weight, cardiovascular and renal targets as well.
For more free education, go to diabetes.knowledgeintopractice.com, where you can see all past episodes of the podcast as well as other free CME resources. Follow us on Twitter (@dkipractice) or connect on LinkedIn.
Disclosures
Prof. Francisco Giorgino:
Grants or contracts: Eli Lilly, Roche Diabetes Care
Consulting: Eli Lilly, Novo Nordisk
Honoraria for lectures, presentations and education events: Astra-Zeneca, Boehringer-Ingelheim
Advisory boards: Eli Lilly, Lifescan, Merck Sharp & Dohme, Medimmune
Leadership or fiduciary role in other board: EASD/EFSD, (SIE), Fo.Ri SIE
Receipt of equipment, materials, drugs, medical writing, gifts or other services: AstraZeneca, Eli Lilly, Novo Nordisk
Unlabelled use of drugs or devices: Roche Diabetes Care, Sanofi
Dr. Vanita Aroda:
Consulting: Applied Therapeutics, Fractyl, Pfizer, Novo Nordisk, Sanofi
Research Support: Applied Therapeutics, Eli Lilly, Fractyl, Novo Nordisk, Sanofi
Target Audience:
Specialty: Primary care physicians (PCPs), endocrinologists, cardiologists, diabetologists
Geographic: Global (ex US and UK audiences)
Funding Information:
This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S, has had no influence on the content of this education.